At the signing ceremony (Photo: VNA)Hanoi (VNA) – . (Shire)
will help Vietnam improve the quality of diagnosis, treatment and management of
a number of in the country for the 2018-2023 period.
A (MoU) to this effect was signed by
representatives of the Medical Services Administration under Vietnam’s Health
Ministry and Shire Vietnam in Hanoi on April 20.
Under the MoU, the Singaporean company will also support Vietnam in improving
professional knowledge, implementing policies on rare disease management and
ensuring policies on rare medicine supply in the country, said Luong Ngoc Khue,
Director of the Medical Services Administration.
During the first stage, the two sides will work together to develop a national
guideline to improve the quality of diagnosis, treatment and management of
Haemophilia and Primary Immune Deficiency (PID) as well as to support policy
development on rare diseases in Vietnam.
Linda Seah, head of Southeast Asia Cluster at Shire, said Haemophilia and PID
are complex rare disorders that require continuous medical research and
innovative approach to ensure positive outcome for patients.
The MoU is the first of its kind for Shire in Asia Pacific, aiming not only to
shorten the time for diagnosis but also ensure that patients are well supported
with adequate access to therapy and management over the course of their life-long
conditions, she said.
According to the World Health Organisation (WHO), there are approximately 100
rare diseases reported in Vietnam. It is estimated that almost one in 15
persons, or approximately six million people in the country, suffer from a rare
disease. Vietnam has more than 6,000 haemophilia patients, but only 2,400 have
been detected their disease situation, while PID remains common and adversely
affects the prognosis of these patients. –VNA
Source: VietnamPlus
